Finasteride in the Treatment of Benign Prostatic Hypertrophy: an Update: New Indications for Finasteride Therapy

REFERENCES

• Cabot AT. The question of castration for enlarged prostate. Ann Surg 1896; 24: 265.
   PubMedGoogle Scholar
• White JW. The results of double 1895 castration in hypertrophy of the prostate. Ann Surg 1895; 22: 1.
   PubMedGoogle Scholar
• Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7.
   Google Scholar
• Lacassagne A. Metaplasie epidermoide de la prostate provoquee, chez la souris, par de injections repetees de fortes doses de folliculine. C R Soc Biol (Paris) 1933; 113: 590–2.
   Google Scholar
• Ekman P. Johansson B, Ohlsen H, Ringertz H. Drug therapy in benign prostatic hyperplasia. Scand J Urol Nephrol 1981; Suppl 60: 77–80.
   Google Scholar
• Geller J, Bork R, Roberts T, Newman H, et al. Treatment of benign prostatic hypertrophy with hydro-xyprogesterone caproate. JAMA 1965; 193: 121–8.
   PubMed Web of Science ®Google Scholar
• Scott WW, Wade JC. Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J Urol 1969; 101: 81–5.
   PubMed Web of Science ®Google Scholar
• Bruchovsky N, Wilson JD. The conversion of testoster-one to 5-alpha-androstane-17beta-o1-3-one by rat pros-tate in vivo and in vitro. J Biol Chem 1968; 243: 2012–21.
   PubMed Web of Science ®Google Scholar
• Zuckerman S. The endocrine control of the prostate. Proc R Soc Med 1937: 81–92.
   PubMedGoogle Scholar
• Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5a-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 1974; 186: 1213–5.
   Google Scholar
• Stoner E, Gregg H, Otterbein JJ, Stein E, et al. Administration of MK-906, a 4-azasteroid compound results in marked suppression of serum dihydrotestos-terone in healthy men. Clin Res 1987; 35: 402.
   Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, et al. The effect of Finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–91.
   Google Scholar
• Beisland HO, Binkowitz B, Brekkan E, Ekman P. et al. Scandinavian clinical study of Finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992; 22: 271–7.
   PubMed Web of Science ®Google Scholar
• Fleshner NE, Fair WR. Anti-androgenic effects of the combination of Finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 1996; 78; 6: 907–10.
   PubMedGoogle Scholar
• Ekman P. Maximum efficacy of Finasteride is obtained within 6 months and maintained over 6 years. Eur Urol 1998; 33: 312–7.
   PubMed Web of Science ®Google Scholar
• Stoner E, and members of the Finasteride Study Group. Three-year safety and efficacy data on the use of Finasteride in the treatment of benign prostatic hyper-plasia. Urology 1994; 43: 284–94.
   Google Scholar
• Tammela TLJ, Kontturi MJ. Urodynamic effects of Finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. J Urol 1993; 149: 342.
   PubMed Web of Science ®Google Scholar
• Tammela TLJ, Kontturi MJ. Long-term effects of Finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruc-tion due to benign prostatic hyperplasia. J Urol 1995; 154: 1466–9.
   PubMed Web of Science ®Google Scholar
• Andersen J-T, Ekman P, Wolff H, Beisland HO, et al., and the Scandinavian BPH Study Group. Can Finaster-ide reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46: 631–7.
   Google Scholar
• Nickel JC, Fradet Y, Boake RC, Pommerville PJ, et al., Efficacy and safety of Finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 1996; 155: 1251–9.
   Google Scholar
• Andersen JT, Nickel JC, Marschall VR, Schulman CC, Boyle P. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. CME (Rapid Com-munication) 1997: 839–45.
   Google Scholar
• McConnell JD, et al. The effect of Finasteride on the risk of acute urinary retention and need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557–63.
   PubMed Web of Science ®Google Scholar
• Lieber M, Jackson Fowler J, Castellanos R, Myers FL, et al. PSA is the strongest predictor of BPH-related outcomes: results of a 4-year placebo-controlled trial. J Urol 1998; Suppl 159: 5.
   Google Scholar
• Lepor H, Williford WO, Barry MJ, Brawer MK for Veterans Affairs Study Group. The efficacy of terazosin, Finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533�9.
   Google Scholar
• Boyle P, Gould L, Roehrbom C. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with Finasteride: Meta-analysis of randomized clinical trials. Urology 1996; 48: 3989–405.
   Google Scholar
• Guess HA, Gormley GJ, Stoner E, Oesterling JE. The effect of Finasteride on prostate specific antigen: review of available data. J Urol 1996; 155: 3�9.
   Web of Science ®Google Scholar
• Oesterling JE, Roy J, Aqha A, Krarup T, Lagerkvist M, et al. The biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer, effects of Finasteride. Urology 1998; 51: 58�63.
   Web of Science ®Google Scholar
• Civantos F, Soloway MS. Finasteride (PROSCAR) effect on prostate cancer. J Urol 1996; 155 Suppl: 604A.
   Google Scholar
• Salem CE, Cote RJ, Skinner EC, Pike MC, et al. The effect of Finasteride on prostate gland peripheral zone
   Google Scholar
• Reynolds T. Prostate cancer prevention trial launched. J Natl Cancer Inst 1993; 85: 1633–4.
   PubMedGoogle Scholar
• Brufsky A, Fontaine-Rothe P. Berlande K, et al. Finasteride and flutamide as potency-sparing androablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913–20.
   Google Scholar
• Ornstein DK, Rao GS, Charlton ET, et al. Combined Finasteride and flutamide therapy in men with advanced prostate cancer (cap). J Urol 1998; 155 Suppl 5: 578A.
   Google Scholar
• Carlin BI, Bodner DR, Spimak JP, Resnick MI. Role of Finasteride in the treatment of recussent hematuria secondary to benign prostatic hyperplasia. The Prostate 1997; 31: 180–2.
   PubMed Web of Science ®Google Scholar
• Miller MI, Puchner PJ. Effects of Finasteride on hematuria associated with benign prostatic hyperplasia: Long-term follow-up. Urology 1998; 51: 237–40.
   PubMed Web of Science ®Google Scholar
• Sieber PR, Rommel FM, Huffnagle HW, Breslin JA, et al. The treatment of gross hematuria secondary to prostatic bleeding with Finasteride. J Urol 1998; 159: 1232–3.
   PubMed Web of Science ®Google Scholar
• Moon SY, Moon WC, Choi HR, Gi YJ. Finasteride inhibits angiogenesis and expression of VEGF in human BPH. J Urol 1998; Suppl 159: 352A.
   Google Scholar
• Foley SJ, Kashif KM, Basketter V, Solomon et al. Randomized controlled study evaluating the efficacy of Finasteride in prostatic bleeding. J Urol 1998; Suppl 35:a3A.
   Google Scholar